FindTrial
Sign In

Control of Blood Pressure and Risk Attenuation- Bangladesh, Pakistan & Sri Lanka

Primary Care Strategies to Reduce High Blood Pressure: A Cluster Randomized Trial in Rural Bangladesh, Pakistan and Sri Lanka

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2016/005
Enrollment
Unknown
Registered
2016-02-16
Start date
2016-03-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

1). Study setting- will be carried out selected clusters in Puttalam District. Randomization will be stratified by the distance from the government clinic, and clusters will be randomized in a 1:1 rat

Sponsors

Professor Tazeen Jafar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age >40 years 2. Residing in the selected clusters in Puttalam District 3. Hypertension defined either as: a).Persistently elevated BP (systolic BP ?140 mm Hg or diastolic BP ?90 mm Hg) from each set of last 2 of 3 readings from 2 separate days b). Maintained on anti-hypertensive medications

Exclusion criteria

Exclusion criteria: 1. Permanently bed-ridden individuals too ill to commute to the clinic 2. Pregnancy, individuals with advanced medical disease (on dialysis, liver failure, other systemic diseases)

Design outcomes

Primary

MeasureTime frame
Change in systolic blood pressure from baseline to final follow-up at two year post randomization (both measurements by independent data collectors who will be masked to randomization). Primary cost-effectiveness measure Incremental cost per mm Hg BP reduction from baseline to end of follow-up at two years post randomization and incremental cost per projected CVD disability adjusted life year (DALY) averted. [At two years post randomization ]—

Secondary

MeasureTime frame
BP controlled to target (SBP <140 mm Hg and DBP <90 mm Hg). 2. Composite outcome of death (all cause) 3. Hospital admission due to CHD, heart failure, or stroke 4. Change in antihypertensive medication adherence (Morisky score) 5. Change in BMI, dietary salt intake (urinary excretion) 6. Prevalence of current smokers, incident diabetes, serum lipid levels, and interheart CVD risk score from baseline to final follow-up at two year post randomization 7. Incidence of adverse outcomes (medication side effects, sick days absenteeism, low DALY between randomized groups) 8. Secondary cost-effectiveness measure: Incremental cost per DALY gained from baseline to end of follow-up. [Two years post-randomization ]—

Countries

Bangladesh,Pakistan,Sri Lanka

Contacts

Public ContactProf Asita de Silva

Director

asitades@gmail.comTel: +94 112665266

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026